[Heredity and genetic aspects of Raynaud's disease]
- PMID:16609626
- DOI: 10.1016/s0398-0499(06)76512-x
[Heredity and genetic aspects of Raynaud's disease]
Abstract
The pathophysiology of primary Raynaud's phenomenon (Raynaud's disease) remains uncertain but the transmission of this primary microcirculatory dysregulation seems strongly influenced by genetic factors. For a long time, physicians have found that the hereditary factor plays an important role in the genesis of Raynaud's disease. Familial analysis and twin studies have confirmed the role of an hereditary factor. It seems heterogeneous but pedigree analysis indicates the possibility of an autosomal dominant transmission influenced by sex, in some families, allowing an approach called "reverse genetic" based on linkage analysis. Such an approach has focused on few loci but sequencing of candidate genes for genetic mutations remains negative. Given the supposed heterogeneity of the genetic transmission of Raynaud's disease, diversification of strategies in molecular genetics is suitable with reference to techniques applied to multifactorial heredity.
Similar articles
- Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon.Terwindt GM, Haan J, Ophoff RA, Groenen SM, Storimans CW, Lanser JB, Roos RA, Bleeker-Wagemakers EM, Frants RR, Ferrari MD.Terwindt GM, et al.Brain. 1998 Feb;121 ( Pt 2):303-16. doi: 10.1093/brain/121.2.303.Brain. 1998.PMID:9549508
- Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients.Planchon B, Pistorius MA, Beurrier P, De Faucal P.Planchon B, et al.Angiology. 1994 Aug;45(8):677-86. doi: 10.1177/000331979404500802.Angiology. 1994.PMID:8048777
- The 3p21.1-p21.3 hereditary vascular retinopathy locus increases the risk for Raynaud's phenomenon and migraine.Hottenga JJ, Vanmolkot KR, Kors EE, Kheradmand Kia S, de Jong PT, Haan J, Terwindt GM, Frants RR, Ferrari MD, van den Maagdenberg AM.Hottenga JJ, et al.Cephalalgia. 2005 Dec;25(12):1168-72. doi: 10.1111/j.1468-2982.2005.00994.x.Cephalalgia. 2005.PMID:16305605Clinical Trial.
- Pharmacotherapy of Raynaud's phenomenon.Belch JJ, Ho M.Belch JJ, et al.Drugs. 1996 Nov;52(5):682-95. doi: 10.2165/00003495-199652050-00006.Drugs. 1996.PMID:9118818Review.
- Raynaud's phenomenon.Wigley FM.Wigley FM.Curr Opin Rheumatol. 1993 Nov;5(6):773-84. doi: 10.1097/00002281-199305060-00013.Curr Opin Rheumatol. 1993.PMID:8117541Review.
Cited by
- The diagnosis and treatment of Raynaud's phenomenon: a practical approach.Pope JE.Pope JE.Drugs. 2007;67(4):517-25. doi: 10.2165/00003495-200767040-00003.Drugs. 2007.PMID:17352512Review.
- Raynaud's phenomenon.Haque A, Hughes M.Haque A, et al.Clin Med (Lond). 2020 Nov;20(6):580-587. doi: 10.7861/clinmed.2020-0754.Clin Med (Lond). 2020.PMID:33199324Free PMC article.
- Primary Raynaud's phenomenon in an infant: a case report and review of literature.Sharathkumar AA, Castillo-Caro P.Sharathkumar AA, et al.Pediatr Rheumatol Online J. 2011 Jul 18;9:16. doi: 10.1186/1546-0096-9-16.Pediatr Rheumatol Online J. 2011.PMID:21767369Free PMC article.
- Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms.Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH.Fardoun MM, et al.Front Pharmacol. 2016 Nov 16;7:438. doi: 10.3389/fphar.2016.00438. eCollection 2016.Front Pharmacol. 2016.PMID:27899893Free PMC article.Review.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Medical